Letter to the Editor: SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responses

Cell Immunol. 2024 Jan-Feb:395-396:104772. doi: 10.1016/j.cellimm.2023.104772. Epub 2023 Sep 30.

Authors

Jean Bourhis¹, Xu-Shan Sun², Yungan Tao³

Affiliations

¹ CHUV, Radiation Oncology Department, Bâtiment Hospitalier, Lausanne, Switzerland. Electronic address: jean.bourhis@chuv.ch.
² Department of Radiation Oncology, Nord Franche-Comté de Montbéliard and CHRU de Besançon, Besançon, France.
³ Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.

PMID: 37996259
DOI: 10.1016/j.cellimm.2023.104772

No abstract available

Keywords: Cancer; Cytokine; Human; IAP; SMAC mimetic; T cells; Xevinapant.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antineoplastic Agents* / pharmacology
Apoptosis
Apoptosis Regulatory Proteins
Cell Line, Tumor
Cell Proliferation
Cytokines*
Humans
Inhibitor of Apoptosis Proteins / metabolism
Inhibitor of Apoptosis Proteins / pharmacology
Mitochondrial Proteins / metabolism

Substances

Cytokines
Apoptosis Regulatory Proteins
Antineoplastic Agents
Mitochondrial Proteins
Inhibitor of Apoptosis Proteins